


12/05/02



PTO

Please type a plus sign (+) inside this box →

+

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No.

PC9838B

First Named Inventor or Application Identifier

William J. Curatolo, et al.

Title

Gelatin Encapsulated Solution Dosage Forms of Sertraline

Express Mail Label No.

EV123872128US

PTO/SB/05 (2/98)

Approved for use through 09/30/2000 OMB 0651-0032

Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

10/31/2002

12/05/02

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

ADDRESS TO:

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification [Total Pages 27]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference in Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☐ Drawing(s) (35 U.S.C. 11 3) [Total sheets]
4. ☒ Oath or Declaration [Total pages 3]
 - a. ☐ Newly executed (original or copy)
 - b. ☒ Copy from a prior application (37 CFR §1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
 - i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§1.63(d)(2) and 1.33(b).
5. ☒ Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. ☐ Computer Readable Copy
 - b. ☐ Paper Copy (identical to computer copy)
 - c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 C.F.R. § 3 73(b) Statement ☐ Power of Attorney
(when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ *Small Entity Statement(s) ☐ Statement filed in prior application, Status still proper and desired (PTO/SB/09-12)
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☒ Other: Priority Claim
This application claims priority of PCT/IB98/00936 filed June 16, 1998, Provisional Application No. 60/051,401 filed July 1, 1997, and Non-Provisional Application 09/380,900 filed September 7, 1999.

*NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: 09/ 380,900

 Prior application information: Examiner S. Tran Group/Art Unit: 1615

18. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) 28523 or ☐ Correspondence address below

NAME (Print/type)	Carmella A. O'Gorman	Registration No. (Attorney/Agent)	33,749
Signature	<i>Carmella A. O'Gorman</i>	Date	12/5/02

FEE TRANSMITTAL

Patent fees are subject to annual revision on October 1
These are the fees effective October 1, 2001
Small Entity payments **must** be supported by a small entity statement,
otherwise large entity fees must be paid See Forms PTO/SB/09-12
See 37 C.F.R. §§ 1.27 and 1.28

Total Amount of Payment (\$1,696.00)

Complete if Known

Application Number	To be assigned
Filing Date	Concurrently herewith
First Named Inventor	William J. Curatolo, et al.
Examiner Name	To be assigned
Group/Art Unit	To be assigned
Attorney Docket No.	PC9838B

METHOD OF PAYMENT (check one)

1. ☒ The commissioner is hereby authorized to charge indicated fees and credit any over payments to:
- Deposit Account Number: 16-1445
- Deposit Account Name: Pfizer Inc
- ☒ Charge Any Additional 37 Fee Required Under C.F.R. §§ 1.1.6 and 1.17 ☐ Charge the Issue Fee Set in 37 C.F.R. § 1.1.8 at the Mailing of the Notice of Allowance

2. ☐ Payment Enclosed:
- ☐ Check ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
101	740	201	370	Utility filing fee	740 00
106	330	206	165	Design filing fee	
107	510	207	255	Plant filing fee	
108	740	208	370	Reissue filing fee	
114	160	214	80	Provisional filing fee	

SUBTOTAL (1) (\$) 740 00

2. EXTRA CLAIM FEES

Total Claims	Extra Claims	Fee from below	Fee Paid
22	-20**= 2	18 00	36 00
Independent Claims	1	- 3**= 0	84 00 = 0
Multiple Dependent		280 00	= 0

** or number previously paid, if greater, For Reissues, see below

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	84	202	42	Independent claims in excess of 3
104	280	204	140	Multiple dependent claim, if not paid
109	84	209	42	**Reissue independent claims over original patent
110	18	210	9	**Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) 36.00

FEE CALCULATION (continued)

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late fee or oath	
127	50	227	25	Surcharge-late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
117	920	217	460	Extension for reply within third month	920 00
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Petitions related to provisional applications	
126	180	126	180	Submission of Information Disclosure Statement	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR 1.129(a))	
149	740	249	370	For each additional invention to be examined (37 CFR 1.129(b))	
Other Fee (specify)					
Other Fee (specify)					
*Reduced by Basic Filing Fee Paid				SUBTOTAL (3) (\$)	920.00

SUBMITTED BY

Type or Printed Name	Carmella A. O'Gorman	Date	12/15/02	Complete (if Applicable)	
Signature	<i>Carmella A. O'Gorman</i>			Reg Number	33,749
				Deposit Account User ID	16-1445

COPY

01/05/02 10:00:00

Patent Application
Attorney Docket No. PC9838B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: William J. Curatolo, et al. :

APPLICATION NO.: To be assigned : Examiner: To be assigned

FILING DATE: Concurrently herewith : Group Art Unit: To be assigned

TITLE: Gelatin Encapsulated Solution Dosage Forms of :
Sertraline

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:

PETITION FOR EXTENSION OF TIME PURSUANT TO 37 C.F.R. §1.136(a)

Pursuant to the provisions of 37 C.F.R. §1.136(a), it is requested that the term for response to the Examiner's Action in this application, mailed on June 5, 2002, and having an original period for response of 3 months, which expired on September 5, 2002, be extended by 3 month(s), such that it expires on December 5, 2002.

Authorization is hereby provided to charge the amount of \$920.00 as stated under 37 C.F.R. §1.17, as well as any additional fees required, or to credit any overpayment to Deposit Account No. 16-1445. Two copies of this paper are enclosed.

Respectfully submitted,

Date:

12/5/02

Carmella A. O'Gorman
Carmella A. O'Gorman
Attorney for Applicant(s)
Reg. No. 33,749

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 686-1847